Annual EBITDA:
-$523.98M-$17.66M(-3.49%)Summary
- As of today, NTLA annual EBITDA is -$523.98 million, with the most recent change of -$17.66 million (-3.49%) on December 31, 2024.
- During the last 3 years, NTLA annual EBITDA has fallen by -$263.02 million (-100.79%).
- NTLA annual EBITDA is now -14952.51% below its all-time high of -$3.48 million, reached on December 31, 2014.
Performance
NTLA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$106.54M+$955.00K(+0.89%)Summary
- As of today, NTLA quarterly EBITDA is -$106.54 million, with the most recent change of +$955.00 thousand (+0.89%) on September 30, 2025.
- Over the past year, NTLA quarterly EBITDA has increased by +$35.62 million (+25.06%).
- NTLA quarterly EBITDA is now -9068.76% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$459.73M+$35.62M(+7.19%)Summary
- As of today, NTLA TTM EBITDA is -$459.73 million, with the most recent change of +$35.62 million (+7.19%) on September 30, 2025.
- Over the past year, NTLA TTM EBITDA has increased by +$67.80 million (+12.85%).
- NTLA TTM EBITDA is now -39463.43% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NTLA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -3.5% | +25.1% | +12.8% |
| 3Y3 Years | -100.8% | -2.9% | -9.2% |
| 5Y5 Years | -419.9% | -302.0% | -290.7% |
NTLA EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -100.8% | at low | -2.9% | +25.1% | -10.0% | +12.8% |
| 5Y | 5-Year | -419.9% | at low | -302.0% | +25.2% | -290.7% | +12.8% |
| All-Time | All-Time | >-9999.0% | at low | -9068.8% | +25.2% | >-9999.0% | +12.8% |
NTLA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$106.54M(+0.9%) | -$459.73M(+7.2%) |
| Jun 2025 | - | -$107.50M(+3.9%) | -$495.35M(+5.5%) |
| Mar 2025 | - | -$111.81M(+16.5%) | -$524.30M(-0.1%) |
| Dec 2024 | -$523.98M(-3.5%) | -$133.88M(+5.8%) | -$523.98M(+0.7%) |
| Sep 2024 | - | -$142.16M(-4.2%) | -$527.52M(-2.6%) |
| Jun 2024 | - | -$136.44M(-22.4%) | -$514.18M(-1.2%) |
| Mar 2024 | - | -$111.49M(+18.9%) | -$507.90M(-0.3%) |
| Dec 2023 | -$506.31M(-12.4%) | -$137.43M(-6.7%) | -$506.31M(-6.2%) |
| Sep 2023 | - | -$128.82M(+1.0%) | -$476.94M(-5.6%) |
| Jun 2023 | - | -$130.16M(-18.4%) | -$451.71M(-8.1%) |
| Mar 2023 | - | -$109.91M(-1.7%) | -$418.01M(+7.2%) |
| Dec 2022 | -$450.59M(-72.7%) | -$108.06M(-4.3%) | -$450.59M(-7.0%) |
| Sep 2022 | - | -$103.58M(-7.4%) | -$421.07M(-8.6%) |
| Jun 2022 | - | -$96.46M(+32.3%) | -$387.70M(-8.1%) |
| Mar 2022 | - | -$142.49M(-81.4%) | -$358.62M(-37.4%) |
| Dec 2021 | -$260.96M(-100.3%) | -$78.53M(-11.9%) | -$260.96M(-16.9%) |
| Sep 2021 | - | -$70.21M(-4.2%) | -$223.22M(-24.3%) |
| Jun 2021 | - | -$67.38M(-50.3%) | -$179.51M(-25.0%) |
| Mar 2021 | - | -$44.83M(-9.9%) | -$143.60M(-10.2%) |
| Dec 2020 | -$130.27M | -$40.80M(-54.0%) | -$130.27M(-10.7%) |
| Sep 2020 | - | -$26.50M(+15.8%) | -$117.66M(-2.2%) |
| Jun 2020 | - | -$31.47M(+0.1%) | -$115.11M(-4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$31.51M(-11.8%) | -$109.78M(-8.9%) |
| Dec 2019 | -$100.78M(-16.6%) | -$28.19M(-17.7%) | -$100.78M(-9.4%) |
| Sep 2019 | - | -$23.95M(+8.4%) | -$92.11M(-1.1%) |
| Jun 2019 | - | -$26.14M(-16.1%) | -$91.11M(-4.1%) |
| Mar 2019 | - | -$22.51M(-15.3%) | -$87.50M(-1.3%) |
| Dec 2018 | -$86.41M(-29.8%) | -$19.52M(+14.9%) | -$86.41M(+4.8%) |
| Sep 2018 | - | -$22.95M(-1.9%) | -$90.77M(-9.5%) |
| Jun 2018 | - | -$22.52M(-5.2%) | -$82.91M(-9.5%) |
| Mar 2018 | - | -$21.42M(+10.3%) | -$75.69M(-13.7%) |
| Dec 2017 | -$66.56M(-114.3%) | -$23.88M(-58.3%) | -$66.56M(-25.4%) |
| Sep 2017 | - | -$15.09M(+1.4%) | -$53.10M(-16.8%) |
| Jun 2017 | - | -$15.31M(-24.6%) | -$45.44M(-23.4%) |
| Mar 2017 | - | -$12.29M(-18.0%) | -$36.84M(-18.6%) |
| Dec 2016 | -$31.05M(-137.4%) | -$10.42M(-40.2%) | -$31.05M(-19.5%) |
| Sep 2016 | - | -$7.43M(-10.9%) | -$26.00M(-19.4%) |
| Jun 2016 | - | -$6.70M(-3.0%) | -$21.77M(-18.1%) |
| Mar 2016 | - | -$6.51M(-21.4%) | -$18.43M(-40.9%) |
| Dec 2015 | -$13.08M(-275.8%) | -$5.36M(-67.2%) | -$13.08M(-69.4%) |
| Sep 2015 | - | -$3.21M(+4.5%) | -$7.72M(-71.0%) |
| Jun 2015 | - | -$3.35M(-188.7%) | -$4.52M(-288.7%) |
| Mar 2015 | - | -$1.16M | -$1.16M |
| Dec 2014 | -$3.48M | - | - |
FAQ
- What is Intellia Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Intellia Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Intellia Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Intellia Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of NTLA is -$523.98M
What is the all-time high annual EBITDA for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high annual EBITDA is -$3.48M
What is Intellia Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, NTLA annual EBITDA has changed by -$17.66M (-3.49%)
What is Intellia Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of NTLA is -$106.54M
What is the all-time high quarterly EBITDA for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high quarterly EBITDA is -$1.16M
What is Intellia Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, NTLA quarterly EBITDA has changed by +$35.62M (+25.06%)
What is Intellia Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of NTLA is -$459.73M
What is the all-time high TTM EBITDA for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high TTM EBITDA is -$1.16M
What is Intellia Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, NTLA TTM EBITDA has changed by +$67.80M (+12.85%)